American Academy of Dermatology Annual Meeting: Washington, DC, USA, 1–5 March 2019
This year’s annual meeting of the American Academy of Dermatology attracted over 18,000 attendees, and included over 480 educational sessions from international leaders in the field of dermatology. Here I report on just a few of the new drugs, developments and research that were discussed.
What’s New in Atopic Dermatitis?
In his presentation on “New and Emerging Therapies for Atopic Dermatitis”, Dr David Cohen (New York University School of Medicine, NY, USA) discussed a number of the biologics and Janus kinase (JAK) inhibitors that are currently under development for atopic dermatitis, including lebrikizumab and tralokinumab [both anti-interleukin (IL)-13 monoclonal antibodies (mAb)], nemolizumab (an IL-31 receptor inhibitor mAb), baricitinib (a JAK1/2 inhibitor), upadacitinib and PF-04965842 (both JAK1 inhibitors), and ASN002 (a JAK/SYK inhibitor).
Dupilumab was approved in the USA for use in adults with atopic dermatitis in March 2017. The results of a pivotal phase 3...
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
Kathy Fraser is a salaried employee of Adis/Springer and declares no relevant conflicts of interest.
- 2.Guttman-Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 2018. https://doi.org/10.1016/j.jaad.2018.01.018 (Epub ahead of print).Google Scholar
- 3.Papp KA, Merola JF, Gottlieb AB, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018;79(2):277–286.e10. https://doi.org/10.1016/j.jaad.2018.03.037 (Epub 2018 Mar 30).CrossRefGoogle Scholar
- 4.Gottlieb AB, Blauvelt A, Thaçi D, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol. 2018;79(2):302–314.e6. https://doi.org/10.1016/j.jaad.2018.04.012 (Epub 2018 Apr 13).CrossRefGoogle Scholar
- 5.Gordon K, Reich K, Blauvelt A, et al. Certolizumab pegol for plaque psoriasis: two-year efficacy results from two phase 3 trials (CIMPASI-1 AND CIMPASI-2). Poster 8063. American Academy of Dermatology Annual Meeting, Washington, DC, Mar 1–5; 2019.Google Scholar
- 6.Ryan C, Crowley J, Valdecantos WC, et al. Efficacy of switching to risankizumab compared with continued adalimumab treatment in patients with moderate-to-severe plaque psoriasis. Poster 8110. American Academy of Dermatology Annual Meeting, Washington, DC, Mar 1–5; 2019.Google Scholar
- 7.Cartwright M, Mazzetti A, Moro L, Gerloni M. Pharmacokinetic profile, safety, and tolerability of clascoterone topical cream 1% in subjects with moderate-to-severe acne vulgaris: an open-label phase IIa study. Poster 10066. American Academy of Dermatology Annual Meeting, Washington, DC, Mar 1–5; 2019.Google Scholar
- 9.Blume-Peytavi U, Tanghetti E, Kemény L, et al. A long-term safety and efficacy study of trifarotene 50 μg/g cream in subjects with facial and truncal acne vulgaris. Poster 10074. American Academy of Dermatology Annual Meeting, Washington, DC, Mar 1–5; 2019.Google Scholar
- 11.Moore A, Green LJ, Bruce S, et al. Once-daily oral sarecycline 1.5 mg/kg/day is effective for moderate to severe acne vulgaris: results from two identically designed, phase 3, randomized, double-blind clinical trials. J Drugs Dermatol. 2018;17(9):987–96.Google Scholar